### **Case Study**

# DeepIntent's Healthcare DSP Delivers 9x ROI by Driving New Patient Starts for Rare Disease Drug



## Challenge

A leading pharmaceutical company sought to increase new patient starts for a prophylactic therapy drug that treats HAE (Hereditary Angioedema).

The brand needed an advertising solution capable of raising awareness of the drug among clinically-relevant HCPs who diagnose and/or treat this rare disease.

## **Strategy**

Identify and engage high-value HCPs with DeepIntent's specialized Healthcare DSP

- ❖ Plan: precise, campaign-specific audiences were created using the brand's NPI list and relevant ICD-10 codes¹ to identify HCPs most likely to treat HAE patients
- Activate: providers were targeted within premium, curated inventory with relevant displays ads, across desktop and mobile devices
- Measure & Optimize: performance was optimized in-flight to maximize engagement and spur new patient starts, while minimizing media cost

#### Results



9x ROI

Driven by new patient starts attributed to the campaign



78%

above goal, peak CTR



98%

NPI match rate to our database of 1.6M+ verified and opted-in HCPs

<sup>1</sup> D84.1, Hereditary Angioedema (HAE)

